ERBB2 and breast carcinoma: Characteristics and findings in principal clinical trials carried out with anti‐HER2 mAbs, ICIs, Akt inhibitors, poly‐ADB ribose polymerase (PARP) inhibitors, and CDK inhibitors as first line therapy in advanced breast cancer.